Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Hyperpolarized [1-13C]-Pyruvate Magnetic Resonance Spectroscopic Imaging of Prostate Cancer In Vivo Predicts Efficacy of Targeting the Warburg Effect.

Scroggins BT, Matsuo M, White AO, Saito K, Munasinghe JP, Sourbier C, Yamamoto K, Diaz V, Takakusagi Y, Ichikawa K, Mitchell JB, Krishna MC, Citrin DE.

Clin Cancer Res. 2018 Jul 1;24(13):3137-3148. doi: 10.1158/1078-0432.CCR-17-1957. Epub 2018 Mar 29.

2.

Targeting loss of the Hippo signaling pathway in NF2-deficient papillary kidney cancers.

Sourbier C, Liao PJ, Ricketts CJ, Wei D, Yang Y, Baranes SM, Gibbs BK, Ohanjanian L, Spencer Krane L, Scroggins BT, Keith Killian J, Wei MH, Kijima T, Meltzer PS, Citrin DE, Neckers L, Vocke CD, Marston Linehan W.

Oncotarget. 2018 Jan 10;9(12):10723-10733. doi: 10.18632/oncotarget.24112. eCollection 2018 Feb 13.

3.

Mithramycin A Enhances Tumor Sensitivity to Mitotic Catastrophe Resulting From DNA Damage.

Scroggins BT, Burkeen J, White AO, Chung EJ, Wei D, Chung SI, Valle LF, Patil SS, McKay-Corkum G, Hudak KE, Linehan WM, Citrin DE.

Int J Radiat Oncol Biol Phys. 2018 Feb 1;100(2):344-352. doi: 10.1016/j.ijrobp.2017.09.049. Epub 2017 Oct 12.

4.

IL-13 is a therapeutic target in radiation lung injury.

Chung SI, Horton JA, Ramalingam TR, White AO, Chung EJ, Hudak KE, Scroggins BT, Arron JR, Wynn TA, Citrin DE.

Sci Rep. 2016 Dec 22;6:39714. doi: 10.1038/srep39714.

5.

Truncated Plasminogen Activator Inhibitor-1 Protein Protects From Pulmonary Fibrosis Mediated by Irradiation in a Murine Model.

Chung EJ, McKay-Corkum G, Chung S, White A, Scroggins BT, Mitchell JB, Mulligan-Kehoe MJ, Citrin D.

Int J Radiat Oncol Biol Phys. 2016 Apr 1;94(5):1163-72. doi: 10.1016/j.ijrobp.2015.11.044. Epub 2015 Dec 14.

6.

Client Proteins and Small Molecule Inhibitors Display Distinct Binding Preferences for Constitutive and Stress-Induced HSP90 Isoforms and Their Conformationally Restricted Mutants.

Prince TL, Kijima T, Tatokoro M, Lee S, Tsutsumi S, Yim K, Rivas C, Alarcon S, Schwartz H, Khamit-Kush K, Scroggins BT, Beebe K, Trepel JB, Neckers L.

PLoS One. 2015 Oct 30;10(10):e0141786. doi: 10.1371/journal.pone.0141786. eCollection 2015.

7.

Tonantzitlolone cytotoxicity toward renal cancer cells is PKCθ- and HSF1-dependent.

Sourbier C, Scroggins BT, Mannes PZ, Liao PJ, Siems K, Wolf D, Beutler JA, Linehan WM, Neckers L.

Oncotarget. 2015 Oct 6;6(30):29963-74. doi: 10.18632/oncotarget.4676.

8.

Combined HSP90 and kinase inhibitor therapy: Insights from The Cancer Genome Atlas.

Schwartz H, Scroggins B, Zuehlke A, Kijima T, Beebe K, Mishra A, Neckers L, Prince T.

Cell Stress Chaperones. 2015 Sep;20(5):729-41. doi: 10.1007/s12192-015-0604-1. Epub 2015 Jun 13. Review.

9.

Transforming growth factor alpha is a critical mediator of radiation lung injury.

Chung EJ, Hudak K, Horton JA, White A, Scroggins BT, Vaswani S, Citrin D.

Radiat Res. 2014 Sep;182(3):350-62. doi: 10.1667/RR13625.1. Epub 2014 Aug 12.

10.

Mesenchymal stem cells inhibit cutaneous radiation-induced fibrosis by suppressing chronic inflammation.

Horton JA, Hudak KE, Chung EJ, White AO, Scroggins BT, Burkeen JF, Citrin DE.

Stem Cells. 2013 Oct;31(10):2231-41. doi: 10.1002/stem.1483.

11.

Posttranslational modification and conformational state of heat shock protein 90 differentially affect binding of chemically diverse small molecule inhibitors.

Beebe K, Mollapour M, Scroggins B, Prodromou C, Xu W, Tokita M, Taldone T, Pullen L, Zierer BK, Lee MJ, Trepel J, Buchner J, Bolon D, Chiosis G, Neckers L.

Oncotarget. 2013 Jul;4(7):1065-74.

12.

MEK1/2 inhibition enhances the radiosensitivity of cancer cells by downregulating survival and growth signals mediated by EGFR ligands.

Chung EJ, Urick ME, Kurshan N, Shield W 3rd, Asano H, Smith PD, Scroggins BS, Burkeen J, Citrin DE.

Int J Oncol. 2013 Jun;42(6):2028-36. doi: 10.3892/ijo.2013.1890. Epub 2013 Apr 10.

13.

Targeting heat shock protein 90 for the treatment of malignant pheochromocytoma.

Giubellino A, Sourbier C, Lee MJ, Scroggins B, Bullova P, Landau M, Ying W, Neckers L, Trepel JB, Pacak K.

PLoS One. 2013;8(2):e56083. doi: 10.1371/journal.pone.0056083. Epub 2013 Feb 14.

14.

Englerin A stimulates PKCθ to inhibit insulin signaling and to simultaneously activate HSF1: pharmacologically induced synthetic lethality.

Sourbier C, Scroggins BT, Ratnayake R, Prince TL, Lee S, Lee MJ, Nagy PL, Lee YH, Trepel JB, Beutler JA, Linehan WM, Neckers L.

Cancer Cell. 2013 Feb 11;23(2):228-37. doi: 10.1016/j.ccr.2012.12.007. Epub 2013 Jan 23.

15.

Heat shock protein 90α (HSP90α), a substrate and chaperone of DNA-PK necessary for the apoptotic response.

Solier S, Kohn KW, Scroggins B, Xu W, Trepel J, Neckers L, Pommier Y.

Proc Natl Acad Sci U S A. 2012 Aug 7;109(32):12866-72. doi: 10.1073/pnas.1203617109. Epub 2012 Jul 2.

16.

Dynamic tyrosine phosphorylation modulates cycling of the HSP90-P50(CDC37)-AHA1 chaperone machine.

Xu W, Mollapour M, Prodromou C, Wang S, Scroggins BT, Palchick Z, Beebe K, Siderius M, Lee MJ, Couvillon A, Trepel JB, Miyata Y, Matts R, Neckers L.

Mol Cell. 2012 Aug 10;47(3):434-43. doi: 10.1016/j.molcel.2012.05.015. Epub 2012 Jun 21.

17.

Characterization of the interaction of Aha1 with components of the Hsp90 chaperone machine and client proteins.

Sun L, Prince T, Manjarrez JR, Scroggins BT, Matts RL.

Biochim Biophys Acta. 2012 Jun;1823(6):1092-101. doi: 10.1016/j.bbamcr.2012.03.014. Epub 2012 Apr 5.

18.

Emetine promotes von Hippel-Lindau-independent degradation of hypoxia-inducible factor-2α in clear cell renal carcinoma.

Kong HS, Lee S, Beebe K, Scroggins B, Gupta G, Lee MJ, Jung YJ, Trepel J, Neckers L.

Mol Pharmacol. 2010 Dec;78(6):1072-8. doi: 10.1124/mol.110.066514. Epub 2010 Sep 2.

19.

Swe1Wee1-dependent tyrosine phosphorylation of Hsp90 regulates distinct facets of chaperone function.

Mollapour M, Tsutsumi S, Donnelly AC, Beebe K, Tokita MJ, Lee MJ, Lee S, Morra G, Bourboulia D, Scroggins BT, Colombo G, Blagg BS, Panaretou B, Stetler-Stevenson WG, Trepel JB, Piper PW, Prodromou C, Pearl LH, Neckers L.

Mol Cell. 2010 Feb 12;37(3):333-43. doi: 10.1016/j.molcel.2010.01.005.

20.

Hsp90 charged-linker truncation reverses the functional consequences of weakened hydrophobic contacts in the N domain.

Tsutsumi S, Mollapour M, Graf C, Lee CT, Scroggins BT, Xu W, Haslerova L, Hessling M, Konstantinova AA, Trepel JB, Panaretou B, Buchner J, Mayer MP, Prodromou C, Neckers L.

Nat Struct Mol Biol. 2009 Nov;16(11):1141-7. doi: 10.1038/nsmb.1682. Epub 2009 Oct 18.

PMID:
19838189
21.

Just say NO: nitric oxide regulation of Hsp90.

Scroggins BT, Neckers L.

EMBO Rep. 2009 Oct;10(10):1093-4. doi: 10.1038/embor.2009.212. Epub 2009 Sep 18. No abstract available.

22.

Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen species.

Sudarshan S, Sourbier C, Kong HS, Block K, Valera Romero VA, Yang Y, Galindo C, Mollapour M, Scroggins B, Goode N, Lee MJ, Gourlay CW, Trepel J, Linehan WM, Neckers L.

Mol Cell Biol. 2009 Aug;29(15):4080-90. doi: 10.1128/MCB.00483-09. Epub 2009 May 26.

23.

Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90.

Kang BH, Plescia J, Song HY, Meli M, Colombo G, Beebe K, Scroggins B, Neckers L, Altieri DC.

J Clin Invest. 2009 Mar;119(3):454-64. doi: 10.1172/JCI37613. Epub 2009 Feb 23.

24.

A small molecule cell-impermeant Hsp90 antagonist inhibits tumor cell motility and invasion.

Tsutsumi S, Scroggins B, Koga F, Lee MJ, Trepel J, Felts S, Carreras C, Neckers L.

Oncogene. 2008 Apr 10;27(17):2478-87. Epub 2007 Oct 29.

25.

Post-translational modification of heat-shock protein 90: impact on chaperone function.

Scroggins BT, Neckers L.

Expert Opin Drug Discov. 2007 Oct;2(10):1403-14. doi: 10.1517/17460441.2.10.1403.

PMID:
23484535
26.

An acetylation site in the middle domain of Hsp90 regulates chaperone function.

Scroggins BT, Robzyk K, Wang D, Marcu MG, Tsutsumi S, Beebe K, Cotter RJ, Felts S, Toft D, Karnitz L, Rosen N, Neckers L.

Mol Cell. 2007 Jan 12;25(1):151-9.

27.

Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness.

Eustace BK, Sakurai T, Stewart JK, Yimlamai D, Unger C, Zehetmeier C, Lain B, Torella C, Henning SW, Beste G, Scroggins BT, Neckers L, Ilag LL, Jay DG.

Nat Cell Biol. 2004 Jun;6(6):507-14. Epub 2004 May 16.

PMID:
15146192
28.

High affinity binding of Hsp90 is triggered by multiple discrete segments of its kinase clients.

Scroggins BT, Prince T, Shao J, Uma S, Huang W, Guo Y, Yun BG, Hedman K, Matts RL, Hartson SD.

Biochemistry. 2003 Nov 4;42(43):12550-61.

PMID:
14580201
29.

Differential inhibition of Hsc70 activities by two Hsc70-binding peptides.

Thulasiraman V, Yun BG, Uma S, Gu Y, Scroggins BT, Matts RL.

Biochemistry. 2002 Mar 19;41(11):3742-53.

PMID:
11888292
30.

Hsp90 regulates p50(cdc37) function during the biogenesis of the activeconformation of the heme-regulated eIF2 alpha kinase.

Shao J, Grammatikakis N, Scroggins BT, Uma S, Huang W, Chen JJ, Hartson SD, Matts RL.

J Biol Chem. 2001 Jan 5;276(1):206-14.

31.

p50(cdc37) is a nonexclusive Hsp90 cohort which participates intimately in Hsp90-mediated folding of immature kinase molecules.

Hartson SD, Irwin AD, Shao J, Scroggins BT, Volk L, Huang W, Matts RL.

Biochemistry. 2000 Jun 27;39(25):7631-44.

PMID:
10858314
32.

Effects of geldanamycin, a heat-shock protein 90-binding agent, on T cell function and T cell nonreceptor protein tyrosine kinases.

Yorgin PD, Hartson SD, Fellah AM, Scroggins BT, Huang W, Katsanis E, Couchman JM, Matts RL, Whitesell L.

J Immunol. 2000 Mar 15;164(6):2915-23.

33.

Arthropod venom citrate inhibits phospholipase A2.

Fenton AW, West PR, Odell GV, Hudiburg SM, Ownby CL, Mills JN, Scroggins BT, Shannon SB.

Toxicon. 1995 Jun;33(6):763-70.

PMID:
7676467
34.

Prognostic Nutritional Index: its usefulness as a predictor of clinical course.

Lowe EF, Stein M, Woolley T, Waycaster M, Scroggins B, Acuff R, Smith JT, Lefemine AA.

J Am Coll Nutr. 1983;2(3):231-40.

PMID:
6630796

Supplemental Content

Loading ...
Support Center